Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
87 hedge funds and large institutions have $1.04B invested in Day One Biopharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 29 increasing their positions, 15 reducing their positions, and 11 closing their positions.
209% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 11
185% more call options, than puts
Call options by funds: $7.91M | Put options by funds: $2.78M
143% more capital invested
Capital invested by funds: $430M → $1.04B (+$615M)
93% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 15
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
32% more funds holding
Funds holding: 66 → 87 (+21)
12.68% more ownership
Funds ownership: 69.9% → 82.58% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$26.5M |
| 3 |
Goldman Sachs
New York
|
+$19.2M |
| 4 |
DM
Deerfield Management
New York
|
+$14.7M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$8.95M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$8.03M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.72M |
| 4 |
Millennium Management
New York
|
-$1.62M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$787K |
DAWN Hedge Fund Activity: Q2 2022 in Review
87 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q2 2022, worth a combined $1.04B — up 143% from $430M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new DAWN positions and 11 closed out — a net gain of 23 holders — while 29 added to existing stakes and 15 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $43.7M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $8.95M sold.
- 87 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q2 2022, up from 66 in Q1 2022.
- Funds reported $1.04B of Day One Biopharmaceuticals stock for Q2 2022, up 143% quarter-over-quarter.
- 34 funds opened new Day One Biopharmaceuticals positions in Q2 2022 and 11 closed out, a net change of +23 holders.
- The largest Day One Biopharmaceuticals buyer in Q2 2022 was Fidelity Investments, an estimated $43.7M added.
- The largest Day One Biopharmaceuticals seller in Q2 2022 was Janus Henderson Group, an estimated $8.95M sold.
Based on aggregated 13F filings for Q2 2022.